Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 17/20 | 0.68 |
| ▸ | CASP1 | P29466 | 3/20 | 0.49 |
| ▸ | IL1B | P01584 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7210360 | 0.94 | ELANE (0.66) | ELANE | |
| SCHEMBL7863330 | 0.89 | ELANE (0.70) | ELANECASP1 | |
| SCHEMBL6556446 | 0.86 | ELANE (0.69) | ELANE | |
| SCHEMBL6557614 | 0.82 | ELANE (0.62) | ELANE | |
| SCHEMBL6556086 | 0.81 | ELANE (0.80) | ELANE | |
| SCHEMBL6558297 | 0.81 | ELANE (0.73) | ELANE | |
| SCHEMBL9584587 | 0.81 | ELANE (0.79) | ELANE | |
| SCHEMBL9584142 | 0.81 | ELANE (1.00) | ELANE | |
| SCHEMBL7205622 | 0.80 | ELANE (0.59) | ELANECASP1 | |
| SCHEMBL8762836 | 0.79 | ELANE (0.75) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0752987-B1 | PYRIMIDINYL DERIVATIVES AS INTERLEUKIN INHIBITORS | VERTEX PHARMA (US) | 2003-11-12 | — | — | EP | claimed |
| US-20010003750-A1 | N-(pyrimidinyl)-aspartic acid analogs as interleukin-1beta converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2001-06-14 | — | — | US | claimed |
| US-6162800-A | ENZYME INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2000-12-19 | — | — | US | claimed |
| EP-0752987-A4 | PYRIMIDINYL DERIVATIVES AS INTERLEUKIN INHIBITORS | SANOFI WINTHROP INC (US) | 1997-04-09 | — | — | EP | claimed |
| EP-0752987-A1 | PYRIMIDINYL DERIVATIVES AS INTERLEUKIN INHIBITORS | SANOFI WINTHROP, INC. (US) | 1997-01-15 | — | — | EP | claimed |
| WO-1995026958-A1 | PYRIMIDINYL DERIVATIVES AS INTERLEUKIN INHIBITORS | SANOFI WINTHROP, INC. (US) | 1995-10-12 | — | — | WO | claimed |
| EP-0752987-B1 | PYRIMIDINYL DERIVATIVES AS INTERLEUKIN INHIBITORS | VERTEX PHARMA (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6407080-B2 | USED AS RESEARCH TOOLS IN PHARMACOLOGICAL, DIAGNOSTIC STUDIES AND TREATMENT OF DISEASES IN MAMMALS IN WHICH 1L-BETA-PROTEASE ACTIVITY IS IMPLICATED; ANTIINFLAMMATORY AGENT | VERTEX PHARMACEUTICALS INCORPORATED | 2002-06-18 | — | — | US | disclosed |
| US-6162800-A | ENZYME INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2000-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003750-A1 | N-(pyrimidinyl)-aspartic acid analogs as interleukin-1beta converting enzyme inhibitors | IL1A, IL1B, IL1RN | ELANE 74/4885CASP1 11/4885IL1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.